Cefodizime as a biological response modifier: A review of its in-vivo, ex-vivo and in-vitro immunomodulatory properties

Journal of Antimicrobial Chemotherapy

Volumn 26, Issue , 1990, Pages 37-47

  Labro, M T ^a  

^a BICHAT HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CEFMENOXIME; CEFODIZIME; CEFOPERAZONE; CEFOTAXIME; INTERFERON; INTERLEUKIN 1; LATAMOXEF; BIOLOGICAL RESPONSE MODIFIER; DRUG DERIVATIVE; IMMUNOLOGICAL ADJUVANT;

ANIMAL MODEL; B LYMPHOCYTE; CANDIDA ALBICANS; CLINICAL ARTICLE; CONFERENCE PAPER; ENTEROBACTERIACEAE; EXPERIMENTAL INFECTION; HUMAN; HUMAN CELL; IMMUNOMODULATION; INTRAVENOUS DRUG ADMINISTRATION; MOUSE; NONHUMAN; NORMAL HUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; TOXOPLASMA GONDII; ANIMAL; REVIEW;

ADJUVANTS, IMMUNOLOGIC; ANIMAL; BIOLOGICAL RESPONSE MODIFIERS; CEFOTAXIME; HUMAN;

EID: 0025520511     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/26.suppl_C.37     Document Type: Article

References (56)

1. Berczi, I. (1989). Immunoregulation and neuroendocrine factors. Developmental and Comparative Immunology 13, 329–41.
2. Dammaco, F., Halberg, F. & Carandente, F. (1988). Antimicrobial agents as Biological Response Modifiers (BRM) and chronoimmunomodulation: An emerging relationship. Chronobiologia 15, 25–39.
3. Daschner, F.D. (1985). Antibiotics and host defence with special reference to phagocytosis by human polymorphonuclear leukocytes. Journal of Antimicrobial Chemotherapy 16, 135–141.
4. Dickneite, G. (1984). In Antibiotics and the Immune System with Special Reference to Cefodizime (Schrinner, E.Ed.), pp. 43–7. Hoechst Aktiengesellschaft.
5. Dürckheimer, W., Fischer, D. & Lattrell, R. (1989). New developments in the synthesis and SAR of several series of 2–aminothiazolyl cephalosporins. In Recent Advances in the Chemistry of β-Lactam Antibiotics (P.H. Bentley & R. Southgate, Eds), pp. 49–76. Royal Society of Chemistry.
6. Feld, R. (1989). The compromised host. European Journal of Cancer and Clinical Oncology 25, S1–7.
7. Fietta, A., Bersani, C., Bertoletti, R., Grassi, F.M. & Gialdroni-Grassi, G., (1988). In vitro and ex vivo enhancement of non specific phagocytosis by cefodizime. Chemotherapy 34, 430–6.
8. Finch, R. (1980). Immunomodulating effects of antimicrobials agents. Journal of Antimicrobial Chemotherapy 6, 691–9.
9. Fleischmann, K., Scheunemann, K.H., Schorlemmer, H.U., Dickneite, G., Blumbach, J., Fischer, G. et al. (1989). Immunomodulation by the new synthetic thiazole derivative Tiprotimod. Arzneimittel-Forschung 39, 743–6.
10. Gemmel, C.G. (1984). Potentiation of phagocytosis of pathogenic bacteria by exposure to low concentrations of antibiotics. Journal of Antimicrobial Chemotherapy 13, 407–9.
11. Gillissen, G. (1982). Non specific influence of antibiotics on the course of infectious processes. Infection 10, 128–30.
12. Gillissen, G. (1984). In Antibiotics and the Immune System with Special Reference to Cefodizime (Schrinner, E. Ed.), pp. 46–54. Hoechst Aktiengesellschaft.
13. Gillisen, G. & Pusztai-Markos, Z.S., (1984). Influence of antibiotics on immunologic parameters: Significance in experimental infections. Drugs under Experimental and Clinical Research 10, 813–19.
14. Goetzl, E.J. (Ed.) (1985). Proceedings of a conference on neuromodulation of immunity and hypersensitivity. Journal of Immunology 135, Suppl. 739S–863S.
15. Goto, S., Tsuji, A., Miyazaki, S., Ogawa, M. & Uji, T., (1986). In vitro and in vivo comparative studies of cefodizime and some other cephalosporins. In Proceedings of the IXth International Congress of Infectious and Parasitic Diseases Munich (Marget, W., Lang, W. & Gabler-Sandberger, E., Eds), Vol. II. Bacterial Infections, Antibacterial Chemotherapy, pp. 17–19. Medizin Verlag, Munchen.
16. Guillemin, R., Cohn, M. & Melnechuck, T., (Eds) (1985). Neural Modulation of Immunity. Raven Press, New York.
17. Hanel, H. & Raether, W. (1986). Influence of cefodizime (HR 221) on an experimentally induced Candida vaginitis in rats. In Proceedings of the IXth International Congress of Infectious and Parasitic Diseases Munich (Marget, W., Lang, W. & Gabler-Sandberger, E., Eds), Vol. II. Bacterial Infections, Antibacterial Chemotherapy, pp. 31–2. Medizin Verlag, München.
18. Hauser, W. E. & Remington, J. S., (1982). Effects of antibiotics on the immune response. American Journal of Medicine 72, 711–6.
19. Hungerer, K. D. (1984). In Antibiotics and the Immune System with Special Reference to Cefodizime (Schrinner, E., Ed.), pp. 38–42. Hoechst Aktiengesellschaft
20. Hyodo, A., Higashitani, F., Ishida, N., Inoue, M. & Mitsuhashi S., (1986). In vitro and in vivo antibacterial activity of THR-221 (cefodizime). In Proceedings of the IXth International Congress of Infectious and Parasitic Diseases, Munich (Marget W., Lang, W. & Gabler-Sandberger, E., Eds), Vol. II. Bacterial Infections, Antibacterial Chemotherapy, pp. 19–21, Medizin Verlag, München.
21. Isenberg, H. D. (1988). Pathogenicity and virulence: Another view. Clinical Microbiology Reviews 1, 40–53.
22. Kadurugamuwa, J. L., Anwar, H., Brown, M. R. W. & Zak, O., (1985). Protein antigen of encapsulated K. pneumoniae surface exposed after growth in the presence of subinhibitory concentrations of cephalosporins. Antimicrobial Agents and Chemotherapy 28, 195–9.
23. Klastersky, J. (1989). Infections in compromised hosts: Considerations and preventions. European Journal of Cancer and Clinical Oncology 25, S53–61.
24. Klesel, N. (1984). In Antibiotics and the Immune System with Special Reference to Cefodizime (Schrinner, E., Ed.), pp. 33–4. Hoechst Aktiengesellschaft.
25. Klesel, N., Limbert, M., Seibert, G., Winkler, I. & Schrinner, E. (1984). Cefodizime, an aminothiazolyl cephalosporin. Ill Therapeutic activity against experimentally induced pneumonia in mice. Journal of Antibiotics 38, 1712–8.
26. Knapp, W. (1984). In Antibiotics and the Immune System with Special Reference to Cefodizime (Schrinner, E., Ed.), pp. 8–9. Hoechst Aktiengesellschaft.
27. Labro, M. T., Amit, N., Babin-Chevaye, C. & Hakim, J. (1987a). Cefodizime (HR–221) potentiation of human neutrophil oxygen-independent bactericidal activity. Journal of Antimicrobial Chemotherapy 19, 331–41.
28. Labro, M. T., Babin-Chevaye, C. & Hakim, J. (1986). Effects of cefotaxime and cefodizime on human granulocyte functions in vitro. Journal of Antimicrobial Chemotherapy 18, 233–7.
29. Labro, M. T., Babin-Chevaye, C. & Hakim, J., (1988). Influence of subinhibitory concentrations of ceftriaxone on opsonization and killing of Pseudomonas aeruginosa by human neutrophils. Journal of Antimicrobial Chemotherapy 22, 341–52.
30. Labro, M. T. & El Benna, J. (1990). Comparison of cefodizime with various cephalosporins for their indirect effect on human neutrophil oxidative burst in vitro. Journal of Antimicrobial Chemotherapy 26, Suppl. C, 49–57.
31. Labro, M. T., Pochet, I., Babin-Chevaye, C. & Hakim, J., (1987b). Effect of ceftriaxone-induced alterations of bacteria on neutrophil bactericidal function. Journal of Antimicrobial Chemotherapy 20, 857–69.
32. Lebish, I. J. & Moraski, R. M., (1987). Mechanisms of immunomodulation by drugs. Toxicologic Pathology 15, 338–45.
33. Leyhausen, G., Seibert, G., Maidhof, A. & Müller, W. E. G., (1984). Differential stimulation of lymphocyte cell growth in vitro by cephalosporins. Antimicrobial Agents and Chemotherapy 26, 752–6.
34. Limbert, M. (1984). In Antibiotics and the Immune System with Special Reference to Cefodizime (Schrinner, E., Ed.), pp. 35–7. Hoechst Aktiengesellschaft.
35. Limbert, M., Bartlett, R., Dickneite, G., Klesel, N., Schorlemmer, H. U., Seibert, G. el al(1984). Cefodizime, an aminothiazolyl cephalosporin. IV Influence of the immune system. Journal of Antibiotics 37, 1719–26
36. Mandell, L. A. (1982). Effects of antimicrobial and antineoplastic drugs on the phagocytic and microbicidal function of the polymorphonuclear leukocytes. Review of Infectious Diseases 4, 683–97.
37. Milatovic, D. (1983). Antibiotics and phagocytosis. European Journal of Clinical Microbiology 2, 414–25.
38. Miyake, Y., Tomonaga, M., Tokoh, T., Yamada, Y. & Ishida, N. (1988). Therapeutic efficacy of cefodizime against experimental infections in immunosuppressed mice. Chemotherapy (Tokyo) 36, 128–39.
39. Novick, W. J. (1984). In Antibiotics and the Immune System with Special Reference to Cefodizime (Schrinner, E., Ed.), p. 55. Hoechst Aktiengesellschaft.
40. Ohnishi, H., Inaba, H., Mochizuki, H. & Kosuzume, H., (1984). Mechanism of action of AC-1370 on phagocyte functions. Antimicrobial Agents and Chemotherapy 23, 874–880
41. Ohnishi, H., Kosuzume, H., Inaba, H., Okura, M., Mochizuki, H., Suzuki, Y. et al. (1983). Effects of AC–1370 a new semi-synthetic cephalosporin on phagocyte functions. Antimicrobial Agents and Chemotherapy 23, 874–80
42. Oishi, K., Matsumoto, K., Yamamoto, M., Morito, T. & Yoshida, T. (1989). Stimulatory effect of cefodizime on macrophage-mediated phagocytosis. Journal of Antibiotics 42, 989–992
43. Ono, Y., Ueda, Y., Baba, M., Nishiya, H. & Kunii, 0. (1989). Influence of a subinhibitory concentration of antibiotics on opsono-phagocytic functions of Klebsiella pneumoniae by human phagocytes. Chemotherapy (Tokyo) 37, 1487–90.
44. Ono, Y., Ueda, Y., Baba, M., Nozue, N., Haga, T., Muraoka, A. et al. (1988). Effect of cefodizime (THR–221) on the function of human phagocytic cells. Chemotherapy (Tokyo) 36, 140–8.
45. Ritts, R. E. (1984). In Antibiotics and the Immune System with Special Reference to Cefodizime (Schrinner, E., Ed.), pp. 22–4. Hoechst Aktiengesellschaft.
46. Sanchez de la Peña, S., Wu, J., Halberg, F., Cornélissen, G., Wetterberg, L., Halberg, E., et al. (1988). Immunomodulation by an antibiotic in malaria and aging: Internal endocrine schedule-shift and chronopharmacologic feedsidewards. Chronobiologia 15, 129–82.
47. Shah, P. M., Limbert, M. & Mullner, H., (1987). Influence of cefodizime (HR 221) on immunologic parameters of human volunteers. In Proceedings of the Third International Symposium on the Influence of Antibiotics on the Host-parasite Relationship. Cologne 1987 Abstract 25, p. 17.
48. Schorlemmer, H. U., Dickneite, G., Blumbach, J., Dürckheimer, W. & Sedlacek, H. H., (1989a). Immunomodulation by the new synthetic thiazole derivative Tiprotimod. Arzneimittel-Forschung 39, 1085–9.
49. Schorlemmer, H. U., Dickneite, G., Hänel, H., Dürckheimer, W. & Sedlacek, H. H., (1989b). Immunomodulation by the synthetic thiazole derivative Tiprotimod. Arzneimittel-Forschung 39, 1235–9.
50. Sethi, K. K. (1984). In Antibiotics and the Immune System with Special Reference to Cefodizime (Schrinner, E., Ed.), pp. 16–21. Hoechst Aktiengesellschaft.
51. Talmadge, J. E., Oldham, R. K. & Fidler, I. J. (1984). Practical considerations for the establishment of a screening procedure for the assessment of biological response modifiers. Journal of Biological Response Modifiers 3, 88–109.
52. Vanholder, R., Van Landschoot, N., Dagrosa, E. & Ringoir, S., (1988). Cefodizime: A new cephalosporin with apparent immune-stimulating properties in chronic renal failure. Nephrology Dialysis Transplantation 2, 221–4.
53. Van Rensburg, C. E. J., Anderson, R., Eftychis, H. A. & Jooné, G. H., (1983). Effects of cefotaxime on neutrophil and lymphocyte functions. South African Medical Journal 64, 346–48.
54. Watanabe, Y., Tawara, S., Mine, Y. & Kikuchi, H. (1986). Synergism of cephalosporins at subinhibitory concentrations and polymorphonuclear leukocyte on phagocytic killing of E. coli and its mode of action. Journal of Antibiotics 39, 294–303.
55. Wu, J., Sanchez de la Pena, S., Halberg, F., Comélissen, G., Wetterberg, L., Halberg, E., et al. (1988). Chronosynergistic effects of lighting schedule-shift and cefodizime on plasmacytoma growth and host survival time. Chronobiologia 15, 105–28.
56. Yokota, T., Nozawa, R., Suzuki, E. & Arai, K. (1986). Synergy of antibacterial activity between cefodizime (THR 221) and the serum complement and mouse polymorphonuclear leukocytes (PMNs) and/or macrophages (MO). In Proceedings of the IXth International Congress of Infectious and Parasitic Diseases Munich (Marget, W., Lang, W. & Gabler-Sandberger, E., Eds), Vol. II. Bacterial Infections, Antibacterial Chemotherapy, pp. 29–31, Medizin Verlag, München.